Thrombopoiesis following severe bone marrow injury frequently is delayed, thereby resulting in life-threatening thrombocytopenia for which there are limited treatment options. The reasons for these delays in recovery are not well understood. Protein kinase C (PKC) agonists promote megakaryocyte differentiation in leukemia cell lines and primary cells. However, little is known about the megakaryopoietic effects of PKC agonists on primary CD34+ cells grown in culture or in vivo. Here we present evidence that the novel PKC isoform-selective agonist 3,20 ingenol dibenzoate (IDB) potently stimulates early megakaryopoiesis of human CD34+ cells. In contrast, broad spectrum PKC agonists failed to do so. In vivo, a single intraperitoneal injection of IDB selectively increased platelets in mice without affecting hemoglobin or white counts. Finally, IDB strongly mitigated radiation-induced thrombocytopenia, even when administered 24 hours after irradiation. Our data demonstrate that novel PKC isoform agonists such as IDB may represent a unique therapeutic strategy for accelerating the recovery of platelet counts following severe marrow injury.
References
[1]
Bartley TD, Bogenberger J, Hunt P, Li YS, Lu HS, et al. (1994) Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl. Cell 77: 1117–1124.
[2]
de Sauvage FJ, Hass PE, Spencer SD, Malloy BE, Gurney AL, et al. (1994) Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand. Nature 369: 533–538.
[3]
Archimbaud E, Ottmann OG, Yin JA, Lechner K, Dombret H, et al. (1999) A randomized, double-blind, placebo-controlled study with pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) as an adjunct to chemotherapy for adults with de novo acute myeloid leukemia. Blood 94: 3694–3701.
[4]
Schiffer CA, Miller K, Larson RA, Amrein PC, Antin JH, et al. (2000) A double-blind, placebo-controlled trial of pegylated recombinant human megakaryocyte growth and development factor as an adjunct to induction and consolidation therapy for patients with acute myeloid leukemia. Blood 95: 2530–2535.
[5]
Kaushansky K (2000) Use of thrombopoietic growth factors in acute leukemia. Leukemia 14: 505–508.
[6]
Geissler K, Yin JA, Ganser A, Sanz MA, Szer J, et al. (2003) Prior and concurrent administration of recombinant human megakaryocyte growth and development factor in patients receiving consolidation chemotherapy for de novo acute myeloid leukemia–a randomized, placebo-controlled, double-blind safety and efficacy study. Ann Hematol 82: 677–683.
[7]
McCullough J (2000) Current issues with platelet transfusion in patients with cancer. Semin Hematol 37: 3–10.
[8]
Long MW, Smolen JE, Szczepanski P, Boxer LA (1984) Role of phorbol diesters in in vitro murine megakaryocyte colony formation. J Clin Invest 74: 1686–1692.
[9]
Long MW, Gragowski LL, Heffner CH, Boxer LA (1985) Phorbol diesters stimulate the development of an early murine progenitor cell. The burst-forming unit-megakaryocyte. J Clin Invest 76: 431–438.
[10]
Baatout S (1998) Phorbol esters: useful tools to study megakaryocyte differentiation. Hematol Cell Ther 40: 33–39.
Debili N, Coulombel L, Croisille L, Katz A, Guichard J, et al. (1996) Characterization of a bipotent erythro-megakaryocytic progenitor in human bone marrow. Blood 88: 1284–1296.
[13]
Drachman JG, Griffin JD, Kaushansky K (1995) The c-Mpl ligand (thrombopoietin) stimulates tyrosine phosphorylation of Jak2, Shc, and c-Mpl. J Biol Chem 270: 4979–4982.
[14]
Newton AC (1995) Protein kinase C: structure, function, and regulation. J Biol Chem 270: 28495–28498.
[15]
Hug H, Sarre TF (1993) Protein kinase C isoenzymes: divergence in signal transduction? Biochem J 291: 329–343.
[16]
Hofmann J (1997) The potential for isoenzyme-selective modulation of protein kinase C. Faseb J 11: 649–669.
[17]
Jaken S (1996) Protein kinase C isozymes and substrates. Curr Opin Cell Biol 8: 168–173.
[18]
Dempsey EC, Newton AC, Mochly-Rosen D, Fields AP, Reyland ME, et al. (2000) Protein kinase C isozymes and the regulation of diverse cell responses. Am J Physiol Lung Cell Mol Physiol 279: L429–438.
[19]
Myklebust JH, Smeland EB, Josefsen D, Sioud M (2000) Protein kinase C-alpha isoform is involved in erythropoietin-induced erythroid differentiation of CD34(+) progenitor cells from human bone marrow. Blood 95: 510–518.
[20]
Pierce A, Heyworth CM, Nicholls SE, Spooncer E, Dexter TM, et al. (1998) An activated protein kinase C alpha gives a differentiation signal for hematopoietic progenitor cells and mimicks macrophage colony-stimulating factor-stimulated signaling events. J Cell Biol 140: 1511–1518.
[21]
Racke FK, Wang D, Zaidi Z, Kelley J, Visvader J, et al. (2001) A potential role for protein kinase C-epsilon in regulating megakaryocytic lineage commitment. J Biol Chem 276: 522–528.
[22]
Akashi K, Traver D, Miyamoto T, Weissman IL (2000) A clonogenic common myeloid progenitor that gives rise to all myeloid lineages. Nature 404: 193–197.
[23]
Manz MG, Miyamoto T, Akashi K, Weissman IL (2002) Prospective isolation of human clonogenic common myeloid progenitors. Proc Natl Acad Sci U S A 99: 11872–11877.
[24]
Nakorn TN, Miyamoto T, Weissman IL (2003) Characterization of mouse clonogenic megakaryocyte progenitors. Proc Natl Acad Sci U S A 100: 205–210.
[25]
Clay D, Rubinstein E, Mishal Z, Anjo A, Prenant M, et al. (2001) CD9 and megakaryocyte differentiation. Blood 97: 1982–1989.
[26]
Le Naour F, Francastel C, Prenant M, Lantz O, Boucheix C, et al. (1997) Upregulation of CD9 expression during TPA treatment of K562 cells. Leukemia 11: 1290–1297.
[27]
Whalen AM, Galasinski SC, Shapiro PS, Nahreini TS, Ahn NG (1997) Megakaryocytic differentiation induced by constitutive activation of mitogen-activated protein kinase kinase. Mol Cell Biol 17: 1947–1958.
[28]
Racke FK, Lewandowska K, Goueli S, Goldfarb AN (1997) Sustained activation of the extracellular signal-regulated kinase/mitogen-activated protein kinase pathway is required for megakaryocytic differentiation of K562 cells. J Biol Chem 272: 23366–23370.
[29]
Murphy LO, MacKeigan JP, Blenis J (2004) A network of immediate early gene products propagates subtle differences in mitogen-activated protein kinase signal amplitude and duration. Mol Cell Biol 24: 144–153.
[30]
Racke F, Tanega C, Zeller K, Janiak A, Rosinbum S, et al. (2004) Identification of Signaling-Induced Transcription Pathway Determinants that Influence Erythro-Megakaryocytic Lineage Commitment. ASH Annual Meeting Abstracts 104: 1607.
[31]
Vegiopoulos A, Garcia P, Emambokus N, Frampton J (2006) Coordination of erythropoiesis by the transcription factor c-Myb. Blood 107: 4703–4710.
[32]
Perkins AC, Sharpe AH, Orkin SH (1995) Lethal beta-thalassaemia in mice lacking the erythroid CACCC-transcription factor EKLF. Nature 375: 318–322.
[33]
Tewari R, Gillemans N, Wijgerde M, Nuez B, von Lindern M, et al. (1998) Erythroid Kruppel-like factor (EKLF) is active in primitive and definitive erythroid cells and is required for the function of 5′HS3 of the beta-globin locus control region. Embo J 17: 2334–2341.
[34]
Hart A, Melet F, Grossfeld P, Chien K, Jones C, et al. (2000) Fli-1 is required for murine vascular and megakaryocytic development and is hemizygously deleted in patients with thrombocytopenia. Immunity 13: 167–177.
[35]
Kruse EA, Loughran SJ, Baldwin TM, Josefsson EC, Ellis S, et al. (2009) Dual requirement for the ETS transcription factors Fli-1 and Erg in hematopoietic stem cells and the megakaryocyte lineage. Proc Natl Acad Sci U S A 106: 13814–13819.
[36]
Starck J, Cohet N, Gonnet C, Sarrazin S, Doubeikovskaia Z, et al. (2003) Functional cross-antagonism between transcription factors FLI-1 and EKLF. Mol Cell Biol 23: 1390–1402.
[37]
Cejas PJ, Carlson LM, Zhang J, Padmanabhan S, Kolonias D, et al. (2005) Protein kinase C betaII plays an essential role in dendritic cell differentiation and autoregulates its own expression. J Biol Chem 280: 28412–28423.
[38]
St Louis DC, Woodcock JB, Franzoso G, Blair PJ, Carlson LM, et al. (1999) Evidence for distinct intracellular signaling pathways in CD34+ progenitor to dendritic cell differentiation from a human cell line model. J Immunol 162: 3237–3248.
[39]
Gobbi G, Mirandola P, Sponzilli I, Micheloni C, Malinverno C, et al. (2007) Timing and expression level of protein kinase C epsilon regulate the megakaryocytic differentiation of human CD34 cells. Stem Cells 25: 2322–2329.
[40]
Bassini A, Zauli G, Migliaccio G, Migliaccio AR, Pascuccio M, et al. (1999) Lineage-restricted expression of protein kinase C isoforms in hematopoiesis. Blood 93: 1178–1188.
[41]
Vitale M, Gobbi G, Mirandola P, Ponti C, Sponzilli I, et al. (2006) TNF-related apoptosis-inducing ligand (TRAIL) and erythropoiesis: a role for PKC epsilon. Eur J Histochem 50: 15–18.
[42]
Sandberg ML, Sutton SE, Pletcher MT, Wiltshire T, Tarantino LM, et al. (2005) c-Myb and p300 regulate hematopoietic stem cell proliferation and differentiation. Dev Cell 8: 153–166.
[43]
Hilton DJ, Kile BT, Alexander WS (2009) Mutational inhibition of c-Myb or p300 ameliorates treatment-induced thrombocytopenia. Blood
[44]
Bouilloux F, Juban G, Cohet N, Buet D, Guyot B, et al. (2008) EKLF restricts megakaryocytic differentiation at the benefit of erythrocytic differentiation. Blood 112: 576–584.
[45]
Tallack MR, Perkins AC (2010) Megakaryocyte-erythroid lineage promiscuity in EKLF null mouse blood. Haematologica 95: 144–147.
